Meng (Mona) Jiao Email & Phone Number

Waltham, Massachusetts, United States

Raleigh-Durham, North Carolina Area

--Translational research on target discovery and development • Identified a target through genome-wide CRISPR screening to potentiate immune checkpoint blockade (ICB) therapy; Unraveled the intrinsic and acquired mechanisms of mutation-mediated lung tumor resistance to ICB treatments; Developed a biologic-based therapy to combat resistance with preclinical and clinical evidence. (Manuscript in submission 2024; Nature 2020)• Tested compound combinations and developed a targeted therapy to enhance glioma sensitivity to radiotherapy; Revealed unique tumor signaling and immune responses to drug treatments by next-generation sequencing and computational analysis. (Cancer Res 2024)• Drove in-depth computational analysis of clinical data from various cohorts. Identified a target and a subsequent pro-inflammatory pathway that boosts anti-tumor immunity (iScience 2024)--Collaboration and project management• Fostered cross-functional collaborations with core facility staff, data scientists, and clinicians to provide translational insights into patient stratification and drive the development of targeted and combination therapies. Supported three phase I/II clinical trials.• Collaborated with the legal team on patent filing and the legal contract office to access clinical data.• Skilled in project management and effective communication. Supported two projects with timely reports to meet grant milestones; Mentored two medical students to ensure the completion of two projects. --Skill advancement• Extensive expertise in isolating, culturing, and engineering patient-derived samples (i.e., lung and colon tumors, NK, T), preclinical primary cells, and cell lines. Hands-on experience in tumor and immune cell characterization.• Certified in translational omics data analysis (Purdue University 2018) and data analytics (Google 2024) with proficiency in data mining and analysis.

Greater New York City Area

• Led mechanistic studies to identify signaling pathways crucial for cancer invasion.• Established cell reprogramming with genetic modification, mechanical stress, and drug treatments.• Built a 3D culture model to study mesenchymal-to-amoeboid transition (MAT) for cancer metastasis and traced cell transition via live-cell imaging and fluorescent microscopy.• Conducted cell/non-cell-based assays to determine protein-protein interactions, protein binding sites, and binding affinity.• Adopted CRISPR/Cas9 when just developed to generate knockout cells for functional analysis.

New York City Metropolitan Area

- Mentored three graduate/undergraduate students with experimental design, data analysis, and troubleshooting for cell cycle and cell migration studies. - Developed cell-based assays and determined the roles of target protein in cell plasticity and breast cancer metastasis.

Greater New York City Area

-Taught over 200 pre-med students and guided practical lab activities in Introductory Biology I lab (BISC 1413) and Introductory Biology II lab (BISC 1414).

Greater New York City Area

- Designed and generated plasmids encoding target genes and studied the impact of juvenile hormone (JH) signaling in drosophila metamorphosis. - Predicted and identified regulatory elements (RE) upstream of target genes with computational protein alignments toolkit and determined conserved RE sites that maintain normal metamorphosis.

Beijing City, China

- Identified the critical sites of target protein for dimerization in leukocyte recruitment and activation. - Determined the metabolic responses of engineered leukocytes by HPLC-MS.

Beijing City, China

- Contributed to large-scale antibody production and characterization. - Performed serum preparation, and antigenicity tests using immunoassays (i.e. serum bactericidal assays, ELISA).

Doctor Of Philosophy (Ph.D.), Cell/Cellular And Molecular Biology; Cancer Biology

Bachelor’S Degree, Biotechnology